PIK3CA and alopecia: The findings for other cutaneous AEs related to PI3K inhibitors were insufficient for a meta‐analysis, which includes alopecia (20.3%, 84/414), Stevens‐Johnson syndrome (SJS) (0.50%, 4/808), urticaria (2.52%, 30/1191), skin ulcer (1.04%, 5/480), toxic skin eruption (1.05%, 5/475), toxic epidermal necrolysis (TEN) (0.32%, 1/317), and drug reaction with eosinophilia and systemic symptoms (DRESS) (0.48%, 1/207).